Cargando…

Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories

OBJECTIVES: To investigate the proportion of potentially relevant undisclosed financial ties between clinical practice guideline writers and pharmaceutical companies. DESIGN: Cross-sectional study of a stratified random sample of Australian guidelines and writers. SETTING: Guidelines available from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moynihan, Ray, Lai, Alexandra, Jarvis, Huw, Duggan, Geraint, Goodrick, Stephanie, Beller, Elaine, Bero, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Health Policy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377504/ https://www.ncbi.nlm.nih.gov/pubmed/30813119 http://dx.doi.org/10.1136/bmjopen-2018-025864

Ejemplares similares

Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals
por: Robertson, Jane, et al.
Publicado: (2009)

Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study
por: Parker, Lisa, et al.
Publicado: (2019)

Financial ties between leaders of influential US professional medical associations and industry: cross sectional study
por: Moynihan, Ray, et al.
Publicado: (2020)

Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and overactive bladder syndrome? An Australian cohort study
por: Mintzes, Barbara, et al.
Publicado: (2018)

Regulating pharmaceutical companies’ financial largesse
por: Avraham, Ronen, et al.
Publicado: (2018)

Disclosures Undisclosed
por: Janney, Cory F., et al.
Publicado: (2019)

National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study
por: Lexchin, Joel, et al.
Publicado: (2022)

Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts
por: Mulinari, Shai, et al.
Publicado: (2018)

Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis
por: Rickard, Emily, et al.
Publicado: (2023)

Discrepancy review: a feasibility study of a novel peer review intervention to reduce undisclosed discrepancies between registrations and publications
Publicado: (2022)

Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016
por: Stoll, Marlene, et al.
Publicado: (2020)

Undisclosed payments by pharmaceutical manufacturers to authors of inflammatory bowel disease guidelines in the United States
por: Al Sulais, Eman, et al.
Publicado: (2021)

Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
por: Stoll, Marlene, et al.
Publicado: (2022)

Influence of ESGC Indicators on Financial Performance of Listed Pharmaceutical Companies
por: López-Toro, Alberto A., et al.
Publicado: (2021)

Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare
por: Moynihan, Ray, et al.
Publicado: (2020)

Editorial note: possible undisclosed conflict of interest
Publicado: (2020)

RELATIONSHIP BETWEEN FINANCIAL IMPACT AND COVERAGE OF DRUGS IN AUSTRALIA
por: Mauskopf, Josephine, et al.
Publicado: (2013)

Buyouts of Indian Pharmaceutical Companies by Multinational Pharmaceutical Companies: An Issue of Concern
por: Sreedhar, D, et al.
Publicado: (2011)

Economic and non-economic determinants of Iranian pharmaceutical companies’ financial performance: an empirical study
por: Masoumi, Mohammadreza, et al.
Publicado: (2019)

Assessment of Financial Relationships Between Otorhinolaryngologists and Pharmaceutical Companies in Japan Between 2016 and 2019
por: Kamamoto, Sae, et al.
Publicado: (2023)

The influence of pharmaceutical companies
por: Migone, Paolo
Publicado: (2017)

A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia
por: Fabbri, Alice, et al.
Publicado: (2017)

BBMRI-ERIC as a resource for pharmaceutical and life science industries: the development of biobank-based Expert Centres
por: van Ommen, Gert-Jan B, et al.
Publicado: (2015)

Public Opinions about Overdiagnosis: A National Community Survey
por: Moynihan, Ray, et al.
Publicado: (2015)

Undisclosed cocaine use and chest pain in emergency departments of Spain
por: Burillo-Putze, Guillermo, et al.
Publicado: (2009)

A Quantitative Analysis of Undisclosed Conflicts of Interest in Pharmacology Textbooks
por: Piper, Brian J., et al.
Publicado: (2015)

Edible seaweed-derived constituents: an undisclosed source of neuroprotective compounds
por: Schepers, Melissa, et al.
Publicado: (2019)

Undisclosed exposure to antiretrovirals prior to treatment initiation: An exploratory analysis
por: Mavhandu-Ramarumo, Lufuno G., et al.
Publicado: (2021)

European Registry of Materials: global, unique identifiers for (undisclosed) nanomaterials
por: van Rijn, Jeaphianne, et al.
Publicado: (2022)

Pharmacovigilance in pharmaceutical companies: An overview
por: Mammì, Maria, et al.
Publicado: (2013)

Climate Change as a Factor in the Development of Companies: Corporate Strategies and Guidelines for State Industrial Policy
por: Terent’ev, N. E.
Publicado: (2021)

Can the Relationship between Doctors and Drug Companies Ever Be a Healthy One?
por: D'Arcy, Emma, et al.
Publicado: (2009)

Soft Targets: Nurses and the Pharmaceutical Industry
por: Jutel, Annemarie, et al.
Publicado: (2008)

Interpretation and use of evidence in state policymaking: a qualitative analysis
por: Apollonio, Dorie E, et al.
Publicado: (2017)

Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies
por: Murayama, Anju, et al.
Publicado: (2021)

Corporate financialization, financing constraints, and innovation efficiency—Empirical evidence based on listed Chinese pharmaceutical companies
por: Zhu, Jialin, et al.
Publicado: (2023)

Expanding Disease Definitions in Guidelines and Expert Panel Ties to Industry: A Cross-sectional Study of Common Conditions in the United States
por: Moynihan, Raymond N., et al.
Publicado: (2013)

Interactions between Australian cancer physicians and the pharmaceutical industry: a qualitative study
por: Pokorny, Adrian M J, et al.
Publicado: (2023)

Increasing transparency and accountability in national pharmaceutical systems
por: Paschke, Anne, et al.
Publicado: (2018)

Corrigendum: Edible seaweed-derived constituents: an undisclosed source of neuroprotective compounds
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nf2c7cafuafd2qa95ql0u9esq4